newsfilter
← Latest News
GlobeNewswire·

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

  • Zealand Pharma entered a royalty purchase agreement with Royalty Pharma for economics related to rusfertide (PTG-300) in exchange for USD 100 million.
  • The transaction includes the sale of a 1% royalty on potential future global net sales of rusfertide & regulatory/commercial milestones.
  • Zealand Pharma will receive USD 50 million as an upfront payment upon closing on August 12, 2026, with the remaining USD 50 million due on the first anniversary.
  • Zealand Pharma retains a 0.25% royalty on annual net global sales exceeding USD 1.5 billion, while Royalty Pharma retains 0.75% on sales above that threshold.
  • The funds will be redeployed to support Zealand Pharma's Metabolic Frontier 2030 strategy & key strategic priorities.
  • Rusfertide is a first-in-class therapy for polycythemia vera with a FDA PDUFA goal date in the third quarter of 2026.
  • Takeda is responsible for the global commercialization of rusfertide following a license agreement with Protagonist Therapeutics.
  • The transaction closes on August 12, 2026, with Goodwin advising Zealand Pharma & Covington, Dechert, Jones Day, & Kromann advising Royalty Pharma.